<SEC-DOCUMENT>0001171843-25-000440.txt : 20250127
<SEC-HEADER>0001171843-25-000440.hdr.sgml : 20250127
<ACCEPTANCE-DATETIME>20250127143621
ACCESSION NUMBER:		0001171843-25-000440
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250127

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XBiotech Inc.
		CENTRAL INDEX KEY:			0001626878
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88810
		FILM NUMBER:		25557947

	BUSINESS ADDRESS:	
		STREET 1:		5217 WINNEBAGO LANE
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
		BUSINESS PHONE:		512-386-2900

	MAIL ADDRESS:	
		STREET 1:		5217 WINNEBAGO LANE
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMARD JOHN
		CENTRAL INDEX KEY:			0001639078
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		8201 E RIVERSIDE DRIVE
		STREET 2:		BLDG 4, STE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001171843-16-007906</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SIMARD JOHN -->
          <cik>0001639078</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>8</amendmentNo>
      <securitiesClassTitle>Common Shares, no par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001626878</issuerCik>
        <issuerName>XBIOTECH INC.</issuerName>
        <issuerCusip>98400H102</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>5217 Winnebago Ln</com:street1>
          <com:city>Austin, TX</com:city>
          <com:stateOrCountry>X1</com:stateOrCountry>
          <com:zipCode>78744</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>John Simard</reportingPersonName>
      <citizenshipOrOrganization>Z4</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>6624530.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>6624530.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6624530.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>19.9</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) This amount includes (i) 3,823,166 shares of common stock held by the Reporting Person, (ii) 870,381 shares of common stock issuable upon the exercise of stock options that are immediately exercisable within 60 days of December 31, 2024 held by the Reporting Person, and (iii) 1,930,983 shares of common stock issuable upon conversion of a convertible loan provided by the Reporting Person to the Issuer under a convertible loan agreement between the Reporting Person and the Issuer dated January 3, 2024 (the "Loan Agreement"). At the Reporting Person's election, the balance may be converted to the common stock at any time the loan balance is outstanding at a fixed conversion price equal to the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the Loan Agreement, which was $4.048 per share, subject to a 19.9% cap limiting the number of shares that could be converted under the Loan Agreement based on the Reporting Person's total stock ownership in the Company at the time of conversion. This amount of 1,930,983 shares is calculated based on the formula to cap the Reporting Person's total stock ownership in the Company not to exceed 19.9% of the Company's issued and outstanding common stock on the date such loan conversion is consummated. Without the contractual cap, that amount would be 2,470,355 and the total shares would be 7,163,902.

(2)The percentage is calculated based upon a denominator that includes (i) 30,487,731 shares outstanding as of December 31, 2024 and (ii) an aggregate of 2,801,364 shares that are issuable upon the exercise of stock options and the conversion of the convertible loan by the Reporting Person.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>XBIOTECH INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>5217 Winnebago Ln, Austin, TX 78744</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>John Simard</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>C/O XBiotech Inc., 5217 Winnebago Ln, Austin, TX 78744</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Canada</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>6,624,530</amountBeneficiallyOwned>
        <classPercent>19.9</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>6,624,530 shares</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Not Applicable</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>6,624,530 shares</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Not Applicable</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>John Simard</reportingPersonName>
      <signatureDetails>
        <signature>/s/ John Simard</signature>
        <title>John Simard/President &amp; CEO, XBiotech Inc.</title>
        <date>01/27/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
